GB2583239A - Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease - Google Patents

Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease Download PDF

Info

Publication number
GB2583239A
GB2583239A GB2009078.3A GB202009078A GB2583239A GB 2583239 A GB2583239 A GB 2583239A GB 202009078 A GB202009078 A GB 202009078A GB 2583239 A GB2583239 A GB 2583239A
Authority
GB
United Kingdom
Prior art keywords
therapeutic agent
nox
disease
subject
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2009078.3A
Other versions
GB202009078D0 (en
Inventor
Lee Dugan Laura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of GB202009078D0 publication Critical patent/GB202009078D0/en
Publication of GB2583239A publication Critical patent/GB2583239A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed are methods of reducing age-dependent lysosome impairment and/or treating an age related neurodegenerative disease, fibrotic disease, or rheumatological disease in a subject comprising administering to the subject a therapeutic agent; wherein the therapeutic agent inhibits nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX) or downstream NOX effector.

Claims (20)

V. CLAIMS
1. A method of treating a neurodegenerative disease, fibrotic disease, or rheumatological disease in a subject comprising administering to the subject a therapeutic agent; wherein the therapeutic agent inhibits nicotinamide adenine dinucleotide phosphate (NADPH)- oxidase (NOX) or a downstream NOX effector.
2. The method of claim 1, wherein the neurodegenerative disease comprises Alzheimerâ s disease, Parkinsonâ s disease, Huntingtonâ s disease, spinocervellar ataxia type 1, age- related dementia, lewy body dementia, probably vascular dementia, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
3. The method of claim 1, wherein the NOX is a NOX isoform selected from NOX1, NOX2, NOX3, NOX4, or NOX5
4. The method of claim 1 , wherein the therapeutic agent is a signal transducer and activator of transcription 3 (STAT3) inhibitor, and wherein the therapeutic agent reduces STAT3 mediated NOX activation, thereby causing NOX inhibition.
5. The method of claim 1, wherein the therapeutic agent is an anti-IL-6 antibody or anti inflammatory agent, and wherein the therapeutic agent reduces IL-6 mediated NOX activation, thereby causing NOX inhibition.
6. The method of claim 1, wherein the downstream NOX effector comprises reactive oxygen species, hydrogen peroxide, or superoxide.
7. The method of any of claims 1-6, wherein the therapeutic agent that is a small molecule, antibody, siRNA, antisense oligonucleotide, peptide, or protein.
8. The method of claim 7, wherein the therapeutic agent is a small molecule comprises diphenylene iodonium, Apocynin, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5- methyl-lH-pyrazolo[4,3-c]pyridine-3,6-dione (GKT-831), Rapamycin, dismutazyme, a malonic acid derivative of C60, an acetic acid derivative of C60, or any combination thereof.
9. The method of claim 1, wherein the agent is administered prior to the onset of pathological changes characteristic of a neurodegenerative disease.
10. A method of reducing age-dependent lysosome impairment and/or increasing initiation of autophagy in a subject comprising administering to the subject a therapeutic agent; wherein the therapeutic agent inhibits nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX) or downstream NOX effector.
11. The method of claim 10, wherein the lysosome impairment is present in hippocampal pyramidal neurons and parvalbumin interneurons.
12. The method of claim 10, wherein the NOX is a NOX isoform selected from NOX1, NOX2, NOX3, NOX4, or NOX5
13. The method of claim 10, wherein the downstream NOX effector comprises reactive oxygen species, hydrogen peroxide, or superoxide.
14. The method of claim 10, wherein the therapeutic agent is a signal transducer and activator of transcription 3 (STAT3) inhibitor, and wherein the therapeutic agent STAT3 mediated NOX activation, thereby causing NOX inhibition.
15. The method of claim 10, wherein the therapeutic agent is an anti-IL-6 antibody or anti inflammatory agent, and wherein the therapeutic agent reduces IL-6 mediated NOX activation, thereby causing NOX inhibition.
16. The method of any of claims 10-15, wherein the therapeutic agent is a small molecule, antibody, siRNA, antisense oligonucleotide, peptide, or protein.
17. The method of claim 16, wherein the agent is a small molecule comprises diphenylene iodonium, Apocynin, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-lH- pyrazolo[4,3-c]pyridine-3,6-dione (GKT-831), Rapamycin, dismutazyme, a malonic acid derivative of C60, an acetic acid derivative of C60, or any combination thereof .
18. A method of improving lysosome function in a subject comprising administering to the subject a therapeutic agent; wherein the therapeutic agent reduces reactive oxygen species (ROS), hydrogen peroxide, or superoxide.
19. The method of claim 18, wherein the agent that improves lysosome function by inhibiting ROS, hydrogen peroxide, or superoxide is a small molecule, antibody, siRNA, antisense oligonucleotide, peptide, or protein.
20. The method of claim 19, wherein the agent is a small molecule comprises dismutazyme, a malonic acid derivative of C60, an acetic acid derivative of C60, or any combination thereof.
GB2009078.3A 2017-11-15 2018-11-15 Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease Withdrawn GB2583239A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586527P 2017-11-15 2017-11-15
PCT/US2018/061281 WO2019099671A1 (en) 2017-11-15 2018-11-15 Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
GB202009078D0 GB202009078D0 (en) 2020-07-29
GB2583239A true GB2583239A (en) 2020-10-21

Family

ID=66539156

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2009078.3A Withdrawn GB2583239A (en) 2017-11-15 2018-11-15 Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease

Country Status (12)

Country Link
US (2) US20200354445A1 (en)
EP (1) EP3710114A4 (en)
JP (1) JP2021502971A (en)
KR (1) KR20200088856A (en)
CN (1) CN111601643A (en)
AU (1) AU2018369912A1 (en)
CA (1) CA3082573A1 (en)
GB (1) GB2583239A (en)
IL (1) IL274588A (en)
MX (1) MX2020005029A (en)
RU (1) RU2020115686A (en)
WO (1) WO2019099671A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102632825B1 (en) * 2020-10-21 2024-02-05 순천향대학교 산학협력단 Biomarker composition for diagnosing neurodegenerative diseases comprising NOX4, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079141A2 (en) * 2005-12-30 2007-07-12 University Of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
US20080020977A1 (en) * 2005-11-21 2008-01-24 Russ Lebovitz Use of Fullerenes to Oxidize Reduced Redox Proteins
WO2009052454A2 (en) * 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2013037499A1 (en) * 2011-09-15 2013-03-21 Johann Wolfgang Goethe-Universität Inhibitors of nox4 expression and/or nox4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
KR100522188B1 (en) * 2003-01-20 2005-10-18 주식회사 뉴로테크 Method for inhibition of necrosis induced by neurotrophin
KR20080018874A (en) * 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. Materials and methods for enhanced degradation of mutant proteins associated with human disease
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020977A1 (en) * 2005-11-21 2008-01-24 Russ Lebovitz Use of Fullerenes to Oxidize Reduced Redox Proteins
WO2007079141A2 (en) * 2005-12-30 2007-07-12 University Of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
WO2009052454A2 (en) * 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2013037499A1 (en) * 2011-09-15 2013-03-21 Johann Wolfgang Goethe-Universität Inhibitors of nox4 expression and/or nox4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CUERVO et al. "Age-related decline in chaperone-mediated autophagy,"J Biol Chem, 06 October 2000 (06.10.2000), Vol 275, No. 40, Pgs. 31505-31513. entire document. *
DUGAN et al."IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase"Plos One, 13 May 2009 (13.05.2009), Vol 4, No5, e5518, Pgs. 1-13. entire document *
Hou et al, "NADPH oxidase-derived H202 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinsons disease". Redox Biol, 22 February 2017 (22.02.2017) Vol12, pgs 162-170. entire document *
PAL, et al. "NADPH oxidase promotes Parkinsonian phenotypes by impairing autiphagic flux in an mTORC1-independent fashion in a cellular model of Parkinsons disease,"Sci Rep,10 March 2016 (10.03.2016) Vol.6, No.22866, Pgs 1-13. entire document *
SCHIAVONE et al. "The NADPH oxidase NOX2 mediates loss of parvalbumin interneurons in traumatic brain injury; human autopic immunohistochemical evidence, "Sci Rep, 18 August 2017 (18.08.2017). Vol. 7, No.1 .pgs 1-10. entrire document. *
SHARMA et al. "Apocyanin a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinsons Disease mode," Mol Neurobiol, 17 June 2015 (17.06.2015), Vol 53, Pgs. 3326-3337. entire document. *
Sun et al. "Amelioration of oxidative stress-induced phenotype loss of parvalbumin interneurons might contribute to the beneficail effects of environmental enrichment in a rat model of post-traumatic stress disorder," Behav Brain Res, 11 June 2016 (11.06.2016), Vol. 312, Pgs 84-92. entire document. *

Also Published As

Publication number Publication date
JP2021502971A (en) 2021-02-04
IL274588A (en) 2020-06-30
CN111601643A (en) 2020-08-28
AU2018369912A1 (en) 2020-05-28
RU2020115686A (en) 2021-12-15
EP3710114A4 (en) 2021-12-01
US20220259302A1 (en) 2022-08-18
GB202009078D0 (en) 2020-07-29
EP3710114A1 (en) 2020-09-23
US20200354445A1 (en) 2020-11-12
MX2020005029A (en) 2020-08-13
KR20200088856A (en) 2020-07-23
WO2019099671A1 (en) 2019-05-23
CA3082573A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
Lee et al. Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-κB pathway in human dermal fibroblasts
Warnecke et al. Activation of the hypoxia‐inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors
Chen et al. Inhibition of Wnt/β-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-β1 and FGF-2
Kaplan et al. Functional, cellular, and molecular remodeling of the heart under influence of oxidative cigarette tobacco smoke
Ross et al. Involvement of NO in contact hypersensitivity.
Fletcher et al. Hypoxia-generated superoxide induces the development of the adhesion phenotype
Dendorfer et al. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals
Liu et al. Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shock
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
Yao et al. Interleukin 4 inhibits high mobility group box-1 protein-mediated NLRP3 inflammasome formation by activating peroxisome proliferator-activated receptor-γ in astrocytes
GB2583239A (en) Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
Tian et al. Resveratrol ameliorates lipopolysaccharide-induced anxiety-like behavior by attenuating YAP-mediated neuro-inflammation and promoting hippocampal autophagy in mice
TJ252B (en) Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv
CA2691368A1 (en) Method for activating regulatory t-cells
Astrike-Davis et al. Targeting cellular senescence as a novel treatment for osteoarthritis
Eckardt et al. Hypoxia-inducible transcription factors and their role in renal disease
ZA200407182B (en) Dexanabinol and dexanabinol analogs regulate inflammation releated genes.
JP2021502971A5 (en)
King et al. Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells
BR0116433A (en) Methods for chronic stress reduction in mammals
KR20120128644A (en) Compounds for use in the treatment of diseases
WO2009146875A1 (en) Pharmaceutical compositions comprising gamma secretase modulators
Liu et al. Dietary supplementation of Huangshan Maofeng green tea preventing hypertension of older C57BL/6 mice induced by desoxycorticosterone acetate and salt
JP5907564B2 (en) Compositions and methods for the treatment of viral diseases
WO2009044294A3 (en) Means and methods for the treatment of cataract and presbyopia

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)